{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:26Z","timestamp":1786979966303,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05647-9","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T22:01:26Z","timestamp":1719266486000},"page":"2659-2668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-0129","authenticated-orcid":false,"given":"Nikolaos","family":"Chaitidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-0484","authenticated-orcid":false,"given":"Zoi","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2822-2872","authenticated-orcid":false,"given":"Stavritsa Taxiarchoula","family":"Varvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8968-1080","authenticated-orcid":false,"given":"Michail","family":"Panagiotidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9747-4466","authenticated-orcid":false,"given":"Ioanna","family":"Katsigianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6761-5673","authenticated-orcid":false,"given":"Grigorios T.","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"11","key":"5647_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H et al (2020) EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 34(11):2461\u20132498. https:\/\/doi.org\/10.1111\/jdv.16915","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"5647_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18(8):465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"5647_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 83(6):706\u2013719. https:\/\/doi.org\/10.1136\/ard-2024-225531","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5647_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5647_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1684\/ejd.2018.3391","volume":"29","author":"S Uchida","year":"2019","unstructured":"Uchida S, Oiso N, Komeda Y, Kudo M, Kawada A (2019) Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. Eur J Dermatol 29(4):444\u2013445. https:\/\/doi.org\/10.1684\/ejd.2018.3391","journal-title":"Eur J Dermatol"},{"issue":"2","key":"5647_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1684\/ejd.2020.3702","volume":"30","author":"R M\u00f6ssner","year":"2020","unstructured":"M\u00f6ssner R, Pinter A (2020) Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases. Eur J Dermatol 30(2):177\u2013178. https:\/\/www.jle.com\/https:\/\/doi.org\/10.1684\/ejd.2020.3702","journal-title":"Eur J Dermatol"},{"issue":"3","key":"5647_CR7","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/dth.12852","volume":"32","author":"F Pirro","year":"2019","unstructured":"Pirro F, Caldarola G, De Simone C, Moretta G, Giovanardi G, Peris K (2019) Multiple paradoxical reactions during ixekizumab therapy. Dermatol Ther 32(3):e12852. https:\/\/doi.org\/10.1111\/dth.12852","journal-title":"Dermatol Ther"},{"issue":"1","key":"5647_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U, Hansel G, Koch A, Sch\u00f6nlebe J, K\u00f6stler E, Haroske G (2008) Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9(1):1\u201314. https:\/\/doi.org\/10.2165\/00128071-200809010-00001","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"5647_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1684\/ejd.2021.4056","volume":"31","author":"A Karamanakos","year":"2021","unstructured":"Karamanakos A, Vergou T, Panopoulos S, Tektonidou MG, Stratigos AJ, Sfikakis PP (2021) Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-\u03b1 therapy. Eur J Dermatol 31(3):307\u2013317. https:\/\/doi.org\/10.1684\/ejd.2021.4056","journal-title":"Eur J Dermatol"},{"issue":"2","key":"5647_CR10","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","volume":"2","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, Aubin F (2016) Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2(2):e000239. https:\/\/doi.org\/10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"issue":"12","key":"5647_CR11","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/acr.22096","volume":"65","author":"MV Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez MV, Sanmart\u00ed R, Ca\u00f1ete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ, BIOBADASER 2.0 Study Group (2013) Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) 65(12):2024\u20132031. https:\/\/doi.org\/10.1002\/acr.22096","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"5647_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639\u2013647. https:\/\/doi.org\/10.1002\/art.22669","journal-title":"Arthritis Rheum"},{"key":"5647_CR13","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","journal-title":"BMJ"},{"issue":"2","key":"5647_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23(2):60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"key":"5647_CR15","doi-asserted-by":"publisher","unstructured":"Noell C, McQuade B, Gottlieb A, Rosmarin D (2017) Anti IL-17 flared psoriasis in a patient on secukinumab. Dermatol Ther 30(4). https:\/\/doi.org\/10.1111\/dth.12505","DOI":"10.1111\/dth.12505"},{"issue":"4","key":"5647_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5070\/D3254043589","volume":"25","author":"\u00c1 Mart\u00ednez-Dom\u00e9nech","year":"2019","unstructured":"Mart\u00ednez-Dom\u00e9nech \u00c1, Garc\u00eda-Legaz-Mart\u00ednez M, Magdaleno-Tapial J, Gi\u00e1caman M, Hern\u00e1ndez-Bel P, P\u00e9rez-Ferriols A (2019) Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis. Dermatol Online J 25(4):14. https:\/\/doi.org\/10.5070\/D3254043589","journal-title":"Dermatol Online J"},{"issue":"11","key":"5647_CR17","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1111\/jdv.15714","volume":"33","author":"CD Sadik","year":"2019","unstructured":"Sadik CD, Thieme M, Zillikens D, Terheyden P (2019) First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol 33(11):e406\u2013e407. https:\/\/doi.org\/10.1111\/jdv.15714","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"5647_CR18","doi-asserted-by":"publisher","first-page":"e13346","DOI":"10.1111\/dth.13346","volume":"33","author":"G Saylam Kurtipek","year":"2020","unstructured":"Saylam Kurtipek G, Zekey E, Tuncez Akyurek F, Akyurek M, Unal M (2020) Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis. Dermatol Ther 33(3):e13346. https:\/\/doi.org\/10.1111\/dth.13346","journal-title":"Dermatol Ther"},{"issue":"6","key":"5647_CR19","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1097\/rhu.0000000000001076","volume":"26","author":"A Abbruzzese","year":"2020","unstructured":"Abbruzzese A, Venerito V, Lopalco G, Fornaro M, Giannotta M, Iannone F (2020) Paradoxical pustular psoriasis in a patient with psoriatic arthritis on Secukinumab Treatment. J Clin Rheumatol 26(6):e208\u2013e209. https:\/\/doi.org\/10.1097\/rhu.0000000000001076","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"5647_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/03009742.2019.1594359","volume":"49","author":"D Currado","year":"2020","unstructured":"Currado D, Margiotta D, Conforti C, Coppola R, Panasiti V, Afeltra A (2020) New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scand J Rheumatol 49(1):75\u201376. https:\/\/doi.org\/10.1080\/03009742.2019.1594359","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"5647_CR21","doi-asserted-by":"publisher","first-page":"e13504","DOI":"10.1111\/dth.13504","volume":"33","author":"K Durmaz","year":"2020","unstructured":"Durmaz K, Ataseven A, Ozer I (2020) Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient. Dermatol Ther 33(4):e13504. https:\/\/doi.org\/10.1111\/dth.13504","journal-title":"Dermatol Ther"},{"issue":"3","key":"5647_CR22","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/dth.13332","volume":"33","author":"M Satoh","year":"2020","unstructured":"Satoh M, Yamamoto T (2020) Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis. Dermatol Ther 33(3):e13332. https:\/\/doi.org\/10.1111\/dth.13332","journal-title":"Dermatol Ther"},{"issue":"8","key":"5647_CR23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/ced.14757","volume":"46","author":"N Hlaca","year":"2021","unstructured":"Hlaca N, Zagar T, Kastelan M, Brajac I, Prpic-Massari L (2021) Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab. Clin Exp Dermatol 46(8):1572\u20131573. https:\/\/doi.org\/10.1111\/ced.14757","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"5647_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.13731","volume":"44","author":"S Dogra","year":"2019","unstructured":"Dogra S, Bishnoi A, Narang T, Handa S (2019) Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol 44(1):72\u201373. https:\/\/doi.org\/10.1111\/ced.13731","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"5647_CR25","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1111\/1346-8138.14463","volume":"45","author":"H Takahashi","year":"2018","unstructured":"Takahashi H, Sato K, Takagi A, Iizuka H (2018) Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis. J Dermatol 45(11):e325\u2013e326. https:\/\/doi.org\/10.1111\/1346-8138.14463","journal-title":"J Dermatol"},{"issue":"12","key":"5647_CR26","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1111\/1346-8138.15082","volume":"46","author":"M Honma","year":"2019","unstructured":"Honma M, Nozaki H, Hayashi K, Iinuma S, Ishida-Yamamoto A (2019) Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab. J Dermatol 46(12):e468\u2013e469. https:\/\/doi.org\/10.1111\/1346-8138.15082","journal-title":"J Dermatol"},{"issue":"8","key":"5647_CR27","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/1346-8138.14842","volume":"46","author":"Y Hosokawa","year":"2019","unstructured":"Hosokawa Y, Hamada T, Ashida H, Ikeda M (2019) Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction. J Dermatol 46(8):e302\u2013e303. https:\/\/doi.org\/10.1111\/1346-8138.14842","journal-title":"J Dermatol"},{"issue":"3","key":"5647_CR28","doi-asserted-by":"publisher","first-page":"AB305","DOI":"10.1016\/j.jaad.2018.05.1203","volume":"79","author":"L Prussick","year":"2018","unstructured":"Prussick L, Noell C, Her M, Alomran A, Abudu M, Rosmarin D (2018) Two cases of anti-interleukin-17 flared psoriasis. J Am Acad Dermatol 79(3):AB305. https:\/\/doi.org\/10.1016\/j.jaad.2018.05.1203","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5647_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2340\/00015555-3138","volume":"99","author":"T Oiwa","year":"2019","unstructured":"Oiwa T, Fujita M, Takase S, Nishimura Y, Ota M, Okada K, Tachibana T (2019) A case of Ixekizumab-induced psoriasiform eruption. Acta Derm Venereol 99(4):446\u2013447. https:\/\/doi.org\/10.2340\/00015555-3138","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"5647_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/cup.13952","volume":"48","author":"TL Tan","year":"2021","unstructured":"Tan TL, Taglia L, Yazdan P (2021) Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy. J Cutan Pathol 48(6):771\u2013774. https:\/\/doi.org\/10.1111\/cup.13952","journal-title":"J Cutan Pathol"},{"key":"5647_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.12688\/f1000research.18493.1","volume":"8","author":"G Tadiotto Cicogna","year":"2019","unstructured":"Tadiotto Cicogna G, Messina F, Nalotto L, Szekely S, Alaibac M (2019) Case Report: paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy. F1000Res 8:336. https:\/\/doi.org\/10.12688\/f1000research.18493.1","journal-title":"F1000Res"},{"issue":"1","key":"5647_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/ddg.14639","volume":"20","author":"M Penalba-Torres","year":"2022","unstructured":"Penalba-Torres M, Rivera-D\u00edaz R (2022) Palmoplantar pustulosis under secukinumab in two patients without psoriasis. J Dtsch Dermatol Ges 20(1):106\u2013109. https:\/\/doi.org\/10.1111\/ddg.14639","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"5647_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/ced.13375","volume":"43","author":"D Hoshina","year":"2018","unstructured":"Hoshina D, Haga N, Furuya K, Sakai M (2018) Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab. Clin Exp Dermatol 43(6):718\u2013719. https:\/\/doi.org\/10.1111\/ced.13375","journal-title":"Clin Exp Dermatol"},{"key":"5647_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4274\/turkderm.galenos.2022.39591","volume":"56","author":"Y G\u00fcrsel \u00dcr\u00fcn","year":"2022","unstructured":"G\u00fcrsel \u00dcr\u00fcn Y, Yelgen H, \u00dcr\u00fcn M, Can N (2022) Secukinumab-induced paradoxical palmoplantar pustular psoriasis. Turkderm-Turk Arch Dermatol Venereol 56:197\u2013199. https:\/\/doi.org\/10.4274\/turkderm.galenos.2022.39591","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"issue":"7","key":"5647_CR35","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1111\/ijd.16686","volume":"62","author":"R Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 R, Boehncke WH, Laffitte E (2023) Paradoxical nail psoriasis induced by the IL-17A inhibitor ixekizumab in palmoplantar pustulosis. Int J Dermatol 62(7):e370\u2013e371. https:\/\/doi.org\/10.1111\/ijd.16686","journal-title":"Int J Dermatol"},{"issue":"11","key":"5647_CR36","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jamadermatol.2017.2826","volume":"153","author":"MJ Sladden","year":"2017","unstructured":"Sladden MJ, Sladden CS, Gulliver WPF (2017) Secukinumab-Induced Psoriasiform Eruption. JAMA Dermatol 153(11):1194\u20131195. https:\/\/doi.org\/10.1001\/jamadermatol.2017.2826","journal-title":"JAMA Dermatol"},{"issue":"2","key":"5647_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/09546634.2020.1782816","volume":"33","author":"M El-Komy","year":"2022","unstructured":"El-Komy M, Amer M, Mostafa A, ElKalioby M (2022) Secukinumab retreatment associated psoriasis flare with pustules. J Dermatolog Treat 33(2):1107\u20131110. https:\/\/doi.org\/10.1080\/09546634.2020.1782816","journal-title":"J Dermatolog Treat"},{"key":"5647_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.dsi.2016.10.002","volume":"35","author":"P Su","year":"2017","unstructured":"Su P, Pan J (2017) Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab. Dermatol Sinica 35:112\u2013113. https:\/\/doi.org\/10.1016\/j.dsi.2016.10.002","journal-title":"Dermatol Sinica"},{"issue":"1","key":"5647_CR39","doi-asserted-by":"publisher","first-page":"2193662","DOI":"10.1080\/09546634.2023.2193662","volume":"34","author":"L Luan","year":"2023","unstructured":"Luan L, Lv C (2023) RETRACTED ARTICLE: Secukinumab-induced paradoxical skin lesions, but successful treatment with tofacitinib in SAPHO syndrome: a case report. J Dermatolog Treat 34(1):2193662. https:\/\/doi.org\/10.1080\/09546634.2023.2193662","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"5647_CR40","doi-asserted-by":"publisher","first-page":"e50726","DOI":"10.7759\/cureus.50726","volume":"15","author":"KA Alnaqbi","year":"2023","unstructured":"Alnaqbi KA, Al Zeyoudi J, Fazal F, Alhaj OM, Jassim I, Albreiki FA (2023) Paradoxical psoriasis and worsening Spondylitis due to Secukinumab in a patient with Ankylosing spondylitis: a Case Report and Literature Review. Cureus 15(12):e50726. https:\/\/doi.org\/10.7759\/cureus.50726","journal-title":"Cureus"},{"key":"5647_CR41","doi-asserted-by":"publisher","first-page":"1364127","DOI":"10.3389\/fmed.2024.1364127","volume":"11","author":"J Ren","year":"2024","unstructured":"Ren J, Deng L, Guo S, Liu H (2024) Paradoxical reaction to IL-17A inhibitor: a case report and literature review. Front Med (Lausanne) 11:1364127. https:\/\/doi.org\/10.3389\/fmed.2024.1364127","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"5647_CR42","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/ijd.14072","volume":"57","author":"FJ Melo","year":"2018","unstructured":"Melo FJ, Magina S (2018) Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 57(12):1521\u20131532. https:\/\/doi.org\/10.1111\/ijd.14072","journal-title":"Int J Dermatol"},{"issue":"1","key":"5647_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.55563\/clinexprheumatol\/rq4k3u","volume":"42","author":"I Sagonas","year":"2024","unstructured":"Sagonas I, Iliopoulos G, Baraliakos X, Daoussis D (2024) Anti-TNF-\u03b1 induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review. Clin Exp Rheumatol 42(1):178\u2013184. https:\/\/doi.org\/10.55563\/clinexprheumatol\/rq4k3u","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"5647_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","volume":"40","author":"AN Collamer","year":"2010","unstructured":"Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40(3):233\u2013240. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.04.003","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5647_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/2475530318810851","volume":"4","author":"SJ Li","year":"2019","unstructured":"Li SJ, Perez-Chada LM, Merola JF (2019) TNF inhibitor-Induced Psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis 4(2):70\u201380. https:\/\/doi.org\/10.1177\/2475530318810851","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"5647_CR46","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.36849\/jdd.7645","volume":"23","author":"MJ Woodbury","year":"2024","unstructured":"Woodbury MJ, Grant C, Perez-Chada L, LaChance AH, Merola JF (2024) A Case Series of TNF inhibitor-Induced Psoriasis successfully treated with Upadacitinib. J Drugs Dermatol 23(2):e60\u2013e63. https:\/\/doi.org\/10.36849\/jdd.7645","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"5647_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/08916934.2014.976630","volume":"48","author":"S Ebihara","year":"2015","unstructured":"Ebihara S, Date F, Dong Y, Ono M (2015) Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity 48(4):259\u2013266. https:\/\/doi.org\/10.3109\/08916934.2014.976630","journal-title":"Autoimmunity"},{"issue":"6","key":"5647_CR48","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/bjd.14075","volume":"173","author":"G Kelly","year":"2015","unstructured":"Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, Fitzgerald R et al (2015) Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 173(6):1431\u20131439. https:\/\/doi.org\/10.1111\/bjd.14075","journal-title":"Br J Dermatol"},{"issue":"11","key":"5647_CR49","doi-asserted-by":"publisher","first-page":"e14108","DOI":"10.1371\/journal.pone.0014108","volume":"5","author":"PC Res","year":"2010","unstructured":"Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MB (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 5(11):e14108. https:\/\/doi.org\/10.1371\/journal.pone.0014108","journal-title":"PLoS ONE"},{"issue":"6","key":"5647_CR50","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/art.40447","volume":"70","author":"L Yang","year":"2018","unstructured":"Yang L, Fanok MH, Mediero-Munoz A, Fogli LK, Corciulo C, Abdollahi S et al (2018) Augmented Th17 differentiation leads to cutaneous and Synovio-Entheseal inflammation in a Novel Model of Psoriatic Arthritis. Arthritis Rheumatol 70(6):855\u2013867. https:\/\/doi.org\/10.1002\/art.40447","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5647_CR51","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1074\/jbc.m308809200","volume":"279","author":"MJ Ruddy","year":"2004","unstructured":"Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, Gaffen SL (2004) Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT\/enhancer-binding protein family members. J Biol Chem 279(4):2559\u20132567. https:\/\/doi.org\/10.1074\/jbc.m308809200","journal-title":"J Biol Chem"},{"issue":"7","key":"5647_CR52","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20060285","volume":"203","author":"C Sutton","year":"2006","unstructured":"Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203(7):1685\u20131691. https:\/\/doi.org\/10.1084\/jem.20060285","journal-title":"J Exp Med"},{"issue":"12","key":"5647_CR53","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.4049\/jimmunol.1200385","volume":"188","author":"GK Griffin","year":"2012","unstructured":"Griffin GK, Newton G, Tarrio ML, Bu D, Maganto-Garcia E, Azcutia V et al (2012) IL-17 and TNF-\u03b1 sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 188(12):6287\u20136299. https:\/\/doi.org\/10.4049\/jimmunol.1200385","journal-title":"J Immunol"},{"issue":"1","key":"5647_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","volume":"9","author":"C Conrad","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA et al (2018) TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 9(1):25. https:\/\/doi.org\/10.1038\/s41467-017-02466-4","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1007\/s00296-024-05687-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000}}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05647-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05647-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05647-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:25:47Z","timestamp":1727285147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05647-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["5647"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05647-9","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00296-024-05687-1","URL":"https:\/\/doi.org\/10.1007\/s00296-024-05687-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}